Herbert GS, et al. - Researchers report initial phase I/IIa trial results of an autologous tumor lysate, particle-loaded, dendritic cell (TLPLDC) vaccine in patients with solid tumors. They assessed the safety of and tumor response (RECIST v1.1) to a personalized vaccine [ created using 1 mg of tumor and 120 ml blood (to isolate DC)] following primary vaccination series (PVS) of four monthly inoculations in patients with any stage solid tumors, ECOG ≤1, and >4 months life-expectancy. They noted that the TLPLDC vaccine was scalable, generated a personalized DC vaccine, and needed little autologous tumor tissue and few DC. The vaccine provoked mainly grade 0–2 toxicities and was found to be safe and provided nearly 40% clinical benefit rate in varied tumors.